Simulation of Clinical Endpoints (Survival, PFS) in Patients With Refractory Multiple Myeloma Treated With Pomalidomide Based on Interim Week 8 M-protein Response

被引：0
|
作者：
Bruno, R. [1 ]
Jonsson, F. [2 ]
Zaki, M. [3 ]
Jacques, C. [3 ]
Richardson, P. [4 ]
Rajkumar, V. S. [5 ]
Claret, L. [1 ]
机构：
[1] Consulting Serv, Marseille, France
[2] Consulting Serv, Stockholm, Sweden
[3] Celgene, Clin Res & Dev, Summit, NJ USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Mayo Clin, Dept Internal Med, Rochester, MN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72492-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S647 / S647
页数：1
相关论文
共 50 条
  • [1] Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response
    Bruno, Rene
    Jonsson, Fredrik
    Zaki, Mohamed
    Jacques, Christian
    Swern, Arlene S.
    Richardson, Paul G.
    Rajkumar, Vincent
    Claret, Laurent
    [J]. BLOOD, 2011, 118 (21) : 821 - 822
  • [2] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
  • [3] Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone plus /- Elotuzumab
    Forslund, Ann
    Tang, Hao
    Duan, Chunzhe
    Popa-McKiver, Mihaela
    Berenson, James R.
    Robbins, Michael
    [J]. BLOOD, 2019, 134
  • [4] OVERALL RESPONSE RATE OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE AFTER LENALIDOMIDE FAILURE: INTERIM RESULTS OF THE POSEIDON STUDY
    Dechow, T.
    Aldaoud, A.
    Hurtz, H. J.
    Knauf, W.
    Groschek, M.
    Hansen, R.
    Mittermueller, J.
    Grebhardt, S.
    Boller, E.
    Potthoff, K.
    [J]. HAEMATOLOGICA, 2016, 101 : 540 - 540
  • [5] MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL
    Liu, S.
    Salem, A.
    Ross, J.
    Bueno, O.
    Badawi, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S67 - S67
  • [6] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Martinez-Lopez, Joaquin
    Chen, Christine
    Spencer, Andrew
    Knop, Stefan
    Bahlis, Nizar J.
    Renner, Christoph
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San Miguel, Jesus F.
    [J]. HAEMATOLOGICA, 2015, 100 (10) : 1327 - 1333
  • [7] Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'
    Lakshman, Arjun
    Ravi, Praful
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    [J]. LEUKEMIA, 2018, 32 (09) : 2083 - 2085
  • [8] Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'
    Arjun Lakshman
    Praful Ravi
    S. Vincent Rajkumar
    Shaji K. Kumar
    [J]. Leukemia, 2018, 32 : 2083 - 2085
  • [9] Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
    Qian, Xiaozhong
    Dimopoulos, Meletios A.
    Amatangelo, Michael
    Bjorklund, Chad
    Towfic, Fadi
    Flynt, Erin
    Weisel, Katja C.
    Ocio, Enrique M.
    Yu, Xin
    Peluso, Teresa
    Sternas, Lars
    Zaki, Mohamed
    Moreau, Philippe
    Thakurta, Anjan
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 462 - 470
  • [10] High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
    J R Mills
    D R Barnidge
    A Dispenzieri
    D L Murray
    [J]. Blood Cancer Journal, 2017, 7 : e590 - e590
12345